A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency

• Published in: Nutrients Vol. 17; no. 4; p. 672
• Main Authors: Pérez-Castrillón, Jose Luis, Jódar-Gimeno, Esteban, Nociar, Ján, Lojka, Michal, Nikolov, Dimitar, Cereto-Castro, Fernando, Novković, Snežana, Tarantino, Umberto, Mehsen-Cetre, Nadia, Arranz, Paula, Martínez Ostalé, Cristina, García-Bea, Aintzane, Gilaberte, Inmaculada
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.02.2025; MDPI
• Subjects: Adult; Aged; Alfacalcidol; Body mass index; Calcifediol; Calcifediol - administration & dosage; Calcifediol - adverse effects; Care and treatment; Clinical trials; Coronaviruses; Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pandemics; Patient compliance; Population; Product development; Treatment Outcome; Vitamin D; Vitamin D - analogs & derivatives; Vitamin D - blood; Vitamin D deficiency; Vitamin D Deficiency - blood; Vitamin D Deficiency - diagnosis; Vitamin D Deficiency - drug therapy; Vitamin deficiency; Italy; Spain; weekly treatment; calcifediol; safety; efficacy; vitamin D deficiency

Given the crucial health benefits of vitamin D, addressing severe deficiencies is a pressing medical concern. This study aimed to evaluate the effectiveness and safety of two new weekly doses of calcifediol (100 µg and 125 µg) for long-term management in patients with severe vitamin D deficiency, de...